Network pharmacology-based strategy to investigate pharmacological mechanisms of Qiaoshao formula for treatment of premature ejaculation

Ming Wang  
Anhui Medical University

Qi Wang  
Shanghai Jiao Tong University School of Medicine

Yongqiang Du  
Anhui Medical University

Xiansheng Zhang (zhangxs2020@126.com)  
First affiliated hospital of anhui medical university

Research

Keywords: Qiaoshao formula, traditional Chinese medicine, premature ejaculation, network pharmacology, module analysis

DOI: https://doi.org/10.21203/rs.3.rs-29052/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background Qiaoshao (QS) formula, a traditional Chinese medicine (TCM) comprising seven herbs, has been clinically proven to have a favorable treatment effect on premature ejaculation (PE). However, its underlying pharmacological mechanisms in the treatment of PE need to be further clarified.

Methods In the present study, a network pharmacology-based strategy was adopted. The active compounds of QS formula were obtained from the Chinese medicine database, and the potential targets of these compounds were collected from the DrugBank database to construct compound-compound targets network. PE-related targets were identified from human disease databases and used to construct the protein-protein interaction (PPI) networks. Compound-disease target PPI network was constructed by merging the PPI network of disease-targets and compound-targets. Cluster and enrichment analyses were performed on the PPI network of disease targets and compound-disease targets.

Results Four primary pharmacological network of QS formula were constructed, including the compound-compound targets network, PPI network of PE-related targets and compounds-disease targets, and the QS-PE mechanism network. The module and pathway enrichment analyses revealed that the QS formula had the potential to affect varieties of biological process and pathways, such as nitric oxide biosynthetic process, oxytocin, thyroid hormone, TNF, PI3K-Akt, and the HIF-1 signaling pathway, that play an important role in the pathogenesis of PE.

Conclusion This study preliminarily discovered the potential targets and pathways of QS formula in the treatment of PE, which laid a good foundation for further experimental research.

Background

Premature ejaculation (PE) is the most common form of male sexual dysfunction with prevalence rates of 20–30%[1]. According to the European Society of Surgeons (ESS), PE is defined as the Intravaginal Ejaculatory Latency Time (IELT) less than 1 minute (primary PE), or the former is shortened to less than 3 minutes (secondary PE), accompanied by the inability to delay ejaculation, and mental health problems[2]. At present, the etiology of PE is still unclear. The mainstream view is that it may be associated with some physiological factors, including serotonin [3], penile hypersensitivity[4], hormones[5], genetic variation [6], prostatitis [7], thyroid and other psychological factors[8,9]. Although PE is not life-threatening, it has serious psychological influences on PE patients, leading to mental distress, anxiety, and depression, which in turn affects the quality of life of patients and their partners.

The treatment of PE needs the implementation of personalized comprehensive treatment according to the specific etiology. At present, treatments for PE mainly include drug therapy, behavioral psychotherapy, surgical treatment, and traditional Chinese medicine (TCM)[10]. Qiaoshao (QS) formula is clinically used to treat lifelong PE (LPE) and can improve satisfaction in sex life. It contains seven Chinese herbal medicines, including Forsythiae Fructus (FF), Paeoniae Radix Alba (PR), Radix Bupleuri (RB), Hedysarum
Multijugum Maxim. (HM), Morindae Officinalis Radix (MO), Rhizoma Dioscoreae (RD), Acoritataninowii Rhizoma (AR). Previous pharmacology research of TCM has been primarily focused on single targets or a few pathways [11,12], which resulted in a lack of acknowledgment of the synergy between multi-component, multiple targets, and multi-pathways in disease treatment of TCM. Currently, the precise molecular mechanisms of QS formula in the treatment of PE remains unclear.

Network pharmacology with systematic and holistic characteristics has been developed in recent years to explore the intricate mechanisms of TCM and extensively applied by TCM researchers [13,14]. To provide evidence for the further in-depth development of the basic experimental research and clinical application of QS formula in PE treatment, we aim to used the network pharmacology to explore the potential mechanisms of how QS formula exerts the therapeutic effects on PE. The flowchart of network pharmacology-based study of QS formula is shown in Fig. 1.

Materials And Methods

Active Ingredients Screening and the Targets

The chemical composition of the seven herbs in the QS formula was retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform [15] (TCMSP, http://lsp.nwu.edu.cn/tcmsp.php). The candidate compounds which have oral bioavailability (OB) ≥ 40% and drug-likeness (DL) ≥ 0.2 were identified as active compounds[16]. A bioactive molecule with high OB displays good DL, which is a qualitative concept utilized in drug design to optimize pharmaceutical and pharmacokinetic properties of molecules, such as chemical stability and solubility[17]. The candidate compounds were then imported into the DrugBank database (https://www.drugbank.ca/) to identify the targets[18].

Searching targets of PE disease

PE-related targets were retrieved from the following four existing resources: 1) Therapeutic Target Database (TTD, http://db.idrblab.net/ttd), 2) DisGeNET (https://www.disgenet.org/), 3) Online Mendelian Inheritance in Man (OMIM, https://www.omim.org/), and 4) GeneCards (https://www.genecards.org/), using the keyword “premature ejaculation” to search. The disease targets obtained from the above databases were pooled to identify targets related to PE.

Network construction

Method for network construction

In order to demonstrate the mechanism of action of the QS formula in the treatment of PE, Several dominating networks were constructed, including the disease PPI network; the drug compounds and compound targets network (C-CT network), the drug compound-disease target network (C-DT network), and the drug compounds disease targets-pathways Network (C-DT-P Network), using the Cytoscape software (version 3.7.1; https://cytoscape.org/download.html)[19]. It can help identify the primary
mechanism of complex TCM in the treatment of diverse diseases. The PPI data was obtained using the Bisogenet plugin in Cytoscape software. Only the interactions between the input nodes were retrieved and presented in the PPI network[20,21]. All self-loop interactions were removed to show PPI directly and concisely.

Bioinformatic analysis and module analysis

GO and KEGG enrichment analysis were carried out using the Database for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov, v6.8)[22]. Enrichment analysis results of the study were screened at FDR < 0.05 and the specific disease pathways were excluded[23]. Molecular Complex Detection (MCODE) algorithms can find dense regions of interaction in PPI networks based on complex connection data[24]. We use the MECODE plugin for Cytoscape software to carry out module analysis on protein targets in the PPI networks according to the default parameters[25,26].

Results

Drug C-T network analysis

Active compounds screening of QSD

A total of 100 active compounds in the QS formula were identified based on the OB and DL parameters, including AR with 4 compounds, FF with 23 compounds, HM with 20 compounds, MO with 20 compounds, PR with 13 compounds, RB with 17 compounds, and RD with 16 compounds. Detailed information on the chemical constituents of each herb and the chemical parameters of the active compounds in QS formula are described in Table S1.

Drug compound-compound target network

Twenty-four of the 100 potentially active compounds without any human targets were removed, and the remaining 76 active compounds with 252 targets were used to construct the C-CT network. The established C-CT network consisted of 335 nodes and 1185 edges, including the seven herbs contained in QS formula, 76 active compounds, and 252 targets constitute the network node. These potentially active ingredients produced a total of 1110 interactions with targets. The number of active ingredients and targets of the seven herbs that were contained in the QS formula Chinese medicine compound in the C-CT network are as follows: MO contains sixteen potentially active ingredients that act on 55 targets; AR includes four potentially active compounds that correspond to 78 targets; HM contains 17 potentially active ingredients and 206 targets; PR includes 8 potentially active ingredients with 81 targets; RD contains 12 potentially active ingredients with 76 targets; RB includes 13 potentially active compounds that correspond to 189 targets; FF contains 19 potentially active ingredients with 220 targets (Table 1).

In this C-CT network, the interactions of the nodes were not in equilibrium. Some compounds can regulate multiple targets (for example, quercetin compounds can act on 147 potential targets, kaempferol can regulate 60 targets, and luteolin can affect 57 potential targets). Conversely, some ingredients can only
affect a few targets, for instance, Cycloartenol, which only affects NR3C protein. Similarly, some targets can be synergistically coordinated by multiple chemical components, while others are only affected by a few compounds. For example, the PTGS2 target can be regulated by 50 compounds, and NCOA2 protein can be regulated by 43 compounds, but some proteins such as CTRB1 and MAOA are regulated by only one compound. The uneven distribution of compounds-target network nodes indicated that QS formula treatment may rely on the role of some key compounds. The network details are described in Fig. 2 and Tables S2.

**Disease target network analysis**

**PE disease-related targets**

From the TTD database, we obtained 5 PE-related proteins, 5 from the OMIM database, 418 (with ) protein from the GeneCard database, and 2 from the Disgenet system. A total of 425 PE disease-related proteins were obtained (Table S3.) and a PPI network of these targets was constructed (Fig. 3). The disease PPI network consisted of 425 nodes and 2197 edges. The closer the node to the center of the network, the higher the degree. Higher degree of a node in the network suggested it is more likely to play an important role in disease development. The protein nodes in the center of PPI network, such as TP53, HSP90AA1, EP300, EGFR, SRC, and MAPK1 have higher degrees, which corresponded to a degree of 71, 69, 66,65, 64, and 62, respectively. Therefore, they may be closely linked to PE development. Network details are described in Table S4.

**Module analysis of the disease PPI network**

The PPI network was clustered by module analysis using the MCODE package and three clusters with score > 4 were used to analyze the mechanism of PE disease (see Table 2 for each type of clustering target, and Figure S1-3 for clustering target relationship). By analyzing the relevant biological processes, molecular functions, and cellular components of every cluster, we found that PE disease was primarily related to the regulation of cell proliferation, gene expression, apoptotic process, immune response, inflammatory response, and other processes. Details of GO enrichment analysis of disease targets and each module are described in Table S5-8.

**The pathway of the PE network**

PE disease-related proteins were put into DAVID for pathway analysis, and 43 pathways were acquired after deleting results for specific disease pathways. The top 5 enriched pathways included the PI3K-Akt signaling pathway contains 89 proteins, the FoxO signaling pathway contains 52 proteins, 34 proteins were enriched in the Prolactin signaling pathway, and 37 proteins were enriched into the TNF signaling pathway, Rap1 signaling pathway contains 50 proteins. The study obtained a pathway of the PE network by aggregating the disease PPI network and PE-related protein pathway analysis. The network directly revealed interactions between disease proteins and the relationship of disease-related pathways. The
The network consists of 291 nodes (43 pathways and 248 PE-related proteins) and 1306 edges. Detailed information on the PE disease pathway is provided in Fig. S4 and Tables S9.

**QS formula-PE network analysis**

QS formula-PE disease target network (C-DT network) was acquired by combining the C-CT network with the disease PPI network. Nodes of herbs and compounds were hidden. The C-DT network succinctly demonstrates the interaction between each active compound in the QS formula and PE disease targets, and multi-component multiple target interactions are presented in a network map. The C-DT network is composed of 88 nodes and 280 edges. Using a Cytoscape plugin (CytoNCA), we selected the following seven topological features to identify candidate targets: betweenness centrality (BC), degree centrality (DC), closeness centrality (CC), eigenvector centrality (EC), network centrality (NC), and local average connectivity (LAC)[27]. The median values of BC, CC, DC, EC, LAC, and NC were 0.018, 0.35, 6, 0.071, 1.927, 2.828, respectively. Thus, we identified 18 key targets with values for these topological features higher than the reported median values and represented by yellow circles in Fig. 4a.

**Module analysis and functional enrichment analysis**

A network module or cluster is defined as a highly interconnected set of nodes that helps discover and reveal hidden biological information within the network. In order to identify the potential mechanism of the QS formula-PE targets, the QS formula-PE PPI network was divided into 3 clusters (Fig. 4b, Table 4). A total of 15 key targets (MYC, ESR1, MAPK1, JUN, PARP1, MAPK8, MAPK14, CDKN2A, PPARG, MDM2, RB1, CASP8, EGFR, TP53, AR) were clustered in these 3 modules.

Next, we performed GO enrichment analysis of the QS formula-PE targets to gain insights into the cellular component (CC), molecular function (MF), and biological processes (BP) that are affected in PE (Tables S10). The results indicated the potential targets were highly connected with the regulation of transcription, apoptotic process, cell proliferation, protein phosphorylation, and nitric oxide biosynthetic process.

Furthermore, KEGG pathway enrichment analysis was carried out for the QS formula-PE targets (Tables S11). The results demonstrated that QS formula-PE targets were highly correlated with signal transduction, immune system, cardiovascular disease, and infectious disease. We recognized 43 PE-related signaling pathways, including the TNF signaling pathway, the PI3K-Akt signaling pathway, and the HIF-1 signaling pathway et al. Therefore, the results imply that QS formula treats PE by participating in above biological process and signaling pathway.

**The YGL capsule C-DT-P network**

The direct and indirect action targets of QS formula were placed in the DAVID database to analyze action pathways. Specific disease pathways were deleted from the results, leaving 20 pathways. The relationships between these proteins and pathways were placed in Cytoscape to construct the pathway of the QS formula-PE network (Figure 5). Details of topological characteristics of the QS formula-PE network
are provided in Table S12. Pathways of the QS formula-PE network only include intersecting target networks that were obtained by merging the pathway of the QS formula-HB network with the QS formula-HB disease targets network. This network consisted of 81 nodes (20 pathways and 60 related proteins), and the relationship between the nodes produced 245 edges. In these 20 pathways, the PI3K-Akt pathway was enriched by 24 proteins and had the highest degree of enrichment; the TNF signaling pathway was enriched by 19 proteins; the FoxO signaling pathway was enriched by 15 proteins; MAPK, T cell receptor and HIF-1 signaling pathway was enriched by 14 proteins; the ErbB signaling pathway was enriched by 13 proteins; the Sphingolipid, Toll-like receptor, Thyroid hormone signaling pathway and Osteoclast differentiation were enriched by 12 proteins; the Cell cycle and Estrogen signaling pathway were enriched by 11 proteins. These pathways may represent the primary mechanisms for how QS formula ameliorates PE disease.

The C-DT-P network could clearly define relationships between herbs, targets, and targets and pathways, but lacked the ability to demonstrate relationships between herbs and compounds. Additionally, due to a large number of nodes and the relationships between the networks, the network is still relatively complicated. To succinctly show the main mechanism of action of QS formula, the H-C-DT-P network and C-DT-P network were merged to obtain the H-C-DT-P network. Targets with linked pathways and compounds with linked targets were retained, the final H-C-DT-P network consisted of seven herbs, 54 compounds, 61 targets, and 20 pathways. Detailed information is provided in Fig. 6.

Discussion

It is currently believed that PE may be caused by 1) psychological reasons: self-confidence, uneasiness; 2) Organic causes: penile hypersensitivity, increased sensory nerve excitability; 3) Others: inflammatory diseases, sympathetic ganglia damage, polycythemia, drug withdrawal syndrome. In this study, the module and enrichment analyses of PE-related targets demonstrated that diverse biological processes were involved in the development of PE, such as transcription regulation, cell proliferation and apoptosis, and signal transduction. The enriched pathways of PE-related targets mainly included 44 pathways, such as PI3K-Akt, TNF, FoxO, and MAPK signaling pathway. Some targets (e.g. MAP2K1, MAP2K2, AKT1, PIK3CG, AKT2, PIK3CA, MAPK1, MAPK3, KRAS, RAF1, PIK3R1, and HRAS) located at the center of the disease-pathway network and act on various pathways, which may hold an important role in the pathogenesis of PE and may be potential targets for future PE treatment.

By merging the C-CT network of QS formula and the PE-targets PPI network, we obtained 88 anti-PE targets from QS formula, then module analysis and enrichment analysis were performed to further investigate the potential mechanism. It revealed that 20 significant enriched pathways were associated with QS formula in the treatment of PE disease, including TNF, PI3K-Akt, HIF-1, T cell receptor, ErbB, FoxO, Toll-like receptor, p53, thyroid hormone, prolactin, sphingolipid, estrogen, VEGF, NOD-like receptor, MAPK, and Fc epsilon RI signaling pathway, as well as osteoclast differentiation, cell cycle, and apoptosis. These pathways participate in many important biological processes, such as signal transduction, regulation of
cell proliferation and gene expression, cellular response to mechanical stimulus, protein phosphorylation, and nitric oxide biosynthetic process.

It is necessary for the occurrence of ejaculation to synergistically active the autonomic and somatic nervous systems. It has been demonstrated that the sympathetic nervous system was able to command the contractile activity of sex glands and related ducts [28, 29]. Synapse is an important part of the nervous system, and many pathways involved in modulating synaptic plasticity, such as TNF [28], PI3K-Akt [29], HIF-1, T cell receptor signaling pathway [30]. The ErbB protein family or EGFR family is a family of four structurally related receptor tyrosine kinases. Insufficient ErbB signaling in humans is related to the development of some neurodegenerative diseases, such as multiple sclerosis and Alzheimer's Disease [31]. Recently, the crucial role of the Nrg-1/ErbB network in neurodevelopment has also been identified [32]. The FOXO family is evolutionarily conserved and a significant arbiter of neural cell fate and function in mammals. Under both physiological and pathological conditions, it could modulate neural cell survival, stress responses, lineage commitment, and neuronal signaling in the process of the neural stem cell to mature neurons [33]. The opioid analgesic tramadol has been reported to be an effective on-demand treatment for PE patients [34]. The activation of Toll-like Receptor-4 could trigger signal transmission pathways in the nervous system, leading to chronic pain as well as opioid tolerance and dependence [35]. The p53 protein is a nuclear transcription factor that regulates the expression of a wide variety of genes involved in diverse biological processes and prevents neurodegeneration by regulating synaptic genes [36]. Therefore, the underlying mechanism of QS in the treatment of PE might be to participate in the management of ejaculation in the nervous system by regulating these crucial pathways.

It has attracted great attention with respect to the role of cerebral serotonin in the control of the ejaculatory response. Oral intake of selective serotonin reuptake inhibitors appeared as effective for patients with PE [37]. In this study, we observed several PE-related targets of were enriched in the serotonin binding, regulation of serotonin secretion, adenylate cyclase-inhibiting serotonin receptor signaling pathway, confirming the crucial role of serotonin in the development of PE. Pharmacological studies have demonstrated that the effect of herbs in QS formula was related to serotonin. The active components of Fructus Forsythiae is St John's wort, which could inhibit the uptake of serotonin, dopamine, and norepinephrine and delay the rapid ejaculation induced by serotonin agonists in a rat model [38]. Morinda officinalis has been proved to decrease the serum level of serotonin [39]. It was reported that the combination use of Radix Bupleuri and Radix Paeoniae Alba could increase serotonin, dopamine, and norepinephrine significantly in a chronic stress rat model [40]. In addition, the level serotonin level in the brain of rats could be increased by Rhizoma Acori Graminei [41].

Non-adrenergic non-cholinergic (NANC) innervation participates in the control of ejaculation by regulating the accessory sex glands activity. In the NANC autonomic system, nitric oxide (NO) fiber is the main component and have been observed in the entire seminal tract of human [42]. In addition, the activity of smooth muscle contractile could be reduced by stimulating the NO intracellular signaling pathway in seminal vesicles [43]. In this study, Go annotation results demonstrated the QS formula-PE targets were
enriched in the nitric oxide biosynthetic process. Several genes may play an important role in the process, including AKT1, EGFR, ESR1, ICAM1, IFNG, IL1B, IL6, MTOR, PTGS2, TNF. Nitric oxide synthesis by endothelial nitric oxide synthase is precisely regulated by protein kinases including AKT1[44], and the quercetin from three herbs of QS formula has been revealed to suppress the protein level of pAKT1[45].

Hormones are dramatically participants in the ejaculatory mechanism[46]. Oxytocin is a neurohypophysial hormone and involves in the regulation of contractility of the male genital tract in some animal species. It has been suggested that oxytocin would play a key role in the central regulation of penile erection as well as in the ejaculatory process, by regulating semen emission [47] and penile detumescence [48]. Specific oxytocin receptors (OTR) have been discovered in the tunica albuginea, epididymis, and vas deferens [49]. OTR in the epididymis was revealed to trigger the release of endothelin to probably amplifies the OX-induced contraction [50]. KEGG enrichment analysis showed that 16 PE-related targets were involved in the oxytocin signaling pathway, and 7 compounds targets of QS formula were involved in the oxytocin signaling pathway, suggesting the potential importance of these 7 targets of QS formula in the treatment of PE. The seven targets were JUN, RAF1, CDKN1A, EGFR, MAPK1, NOS3, PTGS2, respectively. It was reported that the OTR-coupled MAPK-MEF-2A pathway was responsible for OT-induced neurite retraction of hypothalamic neurons[51] and OTR could transactivate EGFR to the different temporal pattern of EGFR[52].

Moreover, thyroid status extremely influences mood and relational life, and patients with thyroid disorders can have various sexual symptoms. It was confirmed that hyperthyroidism affects both the emission and expulsion phases of ejaculation, whereas hypothyroid delayed ejaculation by increasing the latency and decreasing the number and frequency of bulbospongious muscle contractions [53,54]. Both ejaculatory dysfunctions reverted after euthyroidism was achieved without any other treatment for the sexual symptom. This suggests that thyroid hormones directly involved in the physiology of ejaculation. KEGG enrichment analysis of QS formula-PE targets showed that 12 compound targets were enriched in the thyroid hormone signaling pathway, suggesting the potential role of these targets of QS formula in the treatment of PE. Therefore, the potential mechanism of QS formula in PE may be also related to the regulation of 5-HT, nitric oxide, and hormones.

Conclusion

In the present work, we applied a network pharmacology approach to holistically decipher that the pharmacological mechanisms of QS formula in the treatment of PE. The active compounds of QS formula and their targets, PE-related targets were identified, and the networks were constructed to show the interactions among them. The potential mechanisms of QS formula in the treatment of PE may be associated with its involvement into the regulation of signal transduction, 5-HT, nitric oxide, and hormones. However, further experimental experiments were required to validate these hypotheses.

Abbreviations
QS: Qiaoshao; TCM: traditional Chinese medicine; PE: premature ejaculation; PPI: protein-protein interaction; ESS: European Society of Surgeons; IELT: Intravaginal Ejaculatory Latency Time; FF: Forsythiae Fructus; PR: Paeoniae Radix Alba; RB: Radix Bupleuri; HM: Hedysarum Multijugum Maxim.; MO: Morindae Officinalis Radix; RD: Rhizoma Dioscoreae; AR: Acoritatinowii Rhizoma; OB: oral bioavailability; DL: drug-likeness; MCODE: Molecular Complex Detection; CC: cellular component; MF: molecular function; BP: biological processes; NANC: Non-adrenergic non cholinergic; NO: nitric oxide; OTR: oxytocin receptors

Declarations

- Ethics approval and consent to participate

Not applicable

- Consent for publication

Not applicable

- Availability of data and materials

All data generated or analysed during this study are included in this published article.

- Competing interests

The authors declare that they have no competing interests

- Funding

This work was supported by grants from the study was supported by the National Natural Science Foundation of China (81571429).

- Authors' contributions

MW and QW formulated the idea of the article and supervised the research. MW, QW and YQD performed the research, analyzed the data and wrote the manuscript. MW, YQD and XSZ participated in revising the data and improving manuscript writing. All authors reviewed the manuscript, and all authors read and approved the final version of the manuscript.

- Acknowledgements

Not applicable

References
1. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J: The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. *Eur Urol* 2007, 3(51): 816-823, 824.

2. Chung E, Gilbert B, Perera M, Roberts MJ: Premature ejaculation: A clinical review for the general physician. *Aust Fam Physic*ian 2015, 10(44): 737-743.

3. Waldinger MD: The neurobiological approach to premature ejaculation. *J Urol* 2002, 6(168): 2359-2367.

4. Zhang HF, Zhang CY, Li XH, Fu ZZ, Chen ZY: Dorsal penile nerves and primary premature ejaculation. *Chin Med J (Engl)* 2009, 24(122): 3017-3019.

5. Buvat J: Pathophysiology of Premature Ejaculation. *The Journal of Sexual Medicine* 2011, 8): 316-327.

6. Jern P, Santtila P, Witting K, Alanko K, Harlaar N, Johansson A, von der Pahlen B, Varjonen M, Vikstrom N, Algars M, Sandnabba K: Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. *J Sex Med* 2007, 6(4): 1739-1749.

7. Lee JH, Lee SW: Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. *J Sex Med* 2015, 3(12): 697-704.

8. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA: Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. *J Clin Endocrinol Metab* 2005, 12(90): 6472-6479.

9. Corona G, Petrone L, Mannucci E, Jannini EA, Mansani R, Magini A, Giommi R, Forti G, Maggi M: Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. *Eur Urol* 2004, 5(46): 615-622.

10. Gur S, Sikka SC: The characterization, current medications, and promising therapeutics targets for premature ejaculation. *Journal of Andrology* 2015, 3(3): 424-442.

11. Lu WD, Li L, Shen YJ, Zhou R, Yang R, Pang XC, Du GH: [Network pharmacology study of Xiaoxuming Decoction based on vasodilatory and vasoconstrictory related GPCR targets]. *Zhongguo Zhong Yao Za Zhi* 2018, 23(43): 4698-4708.

12. Chen G, Huang C, Liu Y, Chen T, Huang R, Liang M, Zhang J, Xu H: A Network Pharmacology Approach to Uncover the Potential Mechanism of Yinchenensini Decoction. *Evid Based Complement Alternat Med* 2018, 2018): 2178610.

13. Zhang R, Zhu X, Bai H, Ning K: Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. *Front Pharmacol* 2019, 10): 123.

14. Yang Y, Yang K, Hao T, Zhu G, Ling R, Zhou X, Li P: Prediction of Molecular Mechanisms for LianXia NingXin Formula: A Network Pharmacology Study. *Front Physiol* 2018, 9): 489.

15. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y: TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *J Cheminformatics* 2014, 1(6): 13.
16. Li J, Zhao P, Li Y, Tian Y, Wang Y: Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. *Sci Rep-Uk* 2015, 5): 15290.

17. Ma C, Zhai C, Xu T, Lu F, Zhang S, Li C, Wang Q, Cheng F, Wang X: A Systems Pharmacology-Based Study of the Molecular Mechanisms of San Cao Decoction for Treating Hypertension. *Evid-Based Compl Alt* 2019, 2019): 1-10.

18. Vivian L, Craig K, Yannick D, Tim J, Guo AC, Liu Y, Adam M, David A, Michael W, Vanessa N: DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Res* 2013, D1(D1.

19. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003, 11(13): 2498-2504.

20. Runzhi Z, Xue Z, Hong B, Kang N: Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. *Front Pharmacol* 2019, 10): 123.

21. Hu W, Fu W, Wei X, Yang Y, Lu C, Liu Z: A Network Pharmacology Study on the Active Ingredients and Potential Targets of Tripterygium wilfordii Hook for Treatment of Rheumatoid Arthritis. *Evid Based Complement Alternat Med* 2019, 2019): 5276865.

22. Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009, 1(4): 44.

23. Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009, 1(37): 1-13.

24. Bader GD, Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. *Bmc Bioinformatics* 2003, 4): 2.

25. Hogue CW: An automated method for finding molecular complexes in large protein interaction networks.

26. Michael, Boehm, Eva, Nora, Bukosza, Nicole, Huttary, Rebecca, Herzog, Christoph: A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis. *Plos One* 2014, 7(4): 1039-1047.

27. Tang Y, Li M, Wang J, Pan Y, Wu FX: CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. *Biosystems* 2015, 127): 67-72.

28. Maggio N, Vlachos A: Tumor necrosis factor (TNF) modulates synaptic plasticity in a concentration-dependent manner through intracellular calcium stores. *Journal of Molecular Medicine* 2018, 10(96): 1039-1047.

29. Horwood JM, Dufour F, Laroche S, Davis S: Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. *Eur J Neurosci* 2006, 12(23): 3375-3384.

30. Choudhuri K, Llodra J, Roth EW, Tsai J, Gordo S, Wucherpfennig KW, Kam LC, Stokes DL, Dustin ML: Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. *Nature* 2014, 7490(507): 118-123.
31. Wang BJ, Her GM, Hu MK, Chen Y, Tung YT, Wu PY, Hsu W, Lee H, Jin L, Hwang SL: ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease. *P Natl Acad Sci USA* 2017, 15(114):

32. Kataria H, Alizadeh A, Karimiabdolrezaee S: Neuregulin-1/ErbB Network: An Emerging Modulator of Nervous System Injury and Repair. *Prog Neurobiol* 2019, 180): 101643.

33. Santo EE, Paik J: FOXO in Neural Cells and Diseases of the Nervous System. *Curr Top Dev Biol* 2018, 127): 105-118.

34. Kirby EW, Carson CC, Coward RM: Tramadol for the management of premature ejaculation: a timely systematic review. *Int J Impot Res* 2015, 4(27): 121-127.

35. Li J, Csakai A, Jin J, Zhang F, Yin H: Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation. *Chemmedchem* 2016, 2(11): 154-165.

36. Merlo P, Frost B, Peng S, Yang YJ, Park PJ, Feany MB: p53 prevents neurodegeneration by regulating synaptic genes. *P Natl Acad Sci USA* 2014, 50(111): 18055-18060.

37. Giuliano F: 5-hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. *Trends Neurosci* 2007, 2(30): 79-84.

38. Gupta RK, Möller HJ: St. John's Wort. An option for the primary care treatment of depressive patients? *European Archives of Psychiatry & Clinical Neuroscience* 2003, 3(253): 140-148.

39. Zhang P, Chen DL, Lin L, Lin H, Deng T, Wu JS: Effects of Radix Morindaë Officinalis Decoction on contents of monoamine neurotransmitters in brain tissues of natural aging mice. *J Med Res (Chin)* 2014, 43):

40. Li YL, Zhang SL, Zhang LY, Song YL: Effect of Radix Paeoniae Alba Decoction on brain neurotransmitters in chronic stress depression rats. *Zhejiang J Tradit Chin Med (Chin)* 2012, 47):

41. Xie TT, Wang H, Liu P, Wang DX: The influence of Acorus tatarinowii Schott on level of 5-hydroxytryptamine in brain. *Chin J Drug Appl Monit (Chin)* 2007, 4):

42. Sjostrand NO, Ehren I, Eldh J, Wiklund NP: NADPH-diaphorase in glandular cells and nerves and its relation to acetylcholinesterase-positive nerves in the male reproductive tract of man and guinea-pig. *Urol Res* 1998, 3(26): 181-188.

43. Ückert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA: Effects of Phosphodiesterase Inhibitors on the Contractile Responses of Isolated Human Seminal Vesicle Tissue to Adrenergic Stimulation. *J Sex Med* 2008, 2(6): 408-414.

44. Huang J, Cai C, Cheng T, Wu X, Wang D, Zhang K, Xu B, Yan R, Gong H, Zhang J, Shi Y, Xu Z, Zhang X, Zhang X, Shang T, Zhou J, Guo X, Zeng C, Lai EY, Xiao C, Chen J, Wan S, Liu WH, Ke Y, Cheng H: Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling. *Arterioscler Thromb Vasc Biol* 2020, A120314172.

45. Lu J, Wang Z, Li S, Xin Q, Yuan M, Li H, Song X, Gao H, Pervaiz N, Sun X: Quercetin Inhibits the Migration and Invasion of HCCLM3 Cells by Suppressing the Expression of p-Akt1, Matrix
Metalloproteinase (MMP) MMP-2, and MMP-9. Med Sci Monitor 2018, 2(24): 2583-2589.
46. Sansone A, Romanelli F, Jannini EA, Lenzi A: Hormonal correlations of premature ejaculation. Endocrine 2015, 2(49): 333-338.
47. Filippi S, Vignozzi L, Vannelli GB, Ledda F, Forti G, Maggi M: Role of oxytocin in the ejaculatory process. J Endocrinol Invest 2003, 3(26): 82-86.
48. Vignozzi L, Filippi S, Luconi M, Morelli A, Mancina R, Marini M, Vannelli GB, Granchi S, Orlando C, Gelmini S: Oxytocin Receptor Is Expressed in the Penis and Mediates an Estrogen-Dependent Smooth Muscle Contractility. Endocrinology 2004, 4(145): 1823-1834.
49. Maggi M, Malozowski S, Kassis S, Guardabasso V, Rodbard D: Identification and Characterization of Two Classes of Receptors for Oxytocin and Vasopressin in Porcine Tunica Albuginea, Epididymis, and Vas Deferens. Endocrinology 1987, 3(120): 986-994.
50. Filippi S, Vannelli GB, Granchi S, Luconi M, Crescioli C, Mancina R, Natali A, Brocchi S, Vignozzi L, Bencini E: Identification, localization and functional activity of oxytocin receptors in epididymis. Mol Cell Endocrinol 2002, 1(193): 89-100.
51. Meyer M, Berger I, Winter J, Jurek B: Oxytocin alters the morphology of hypothalamic neurons via the transcription factor myocyte enhancer factor 2A (MEF-2A). Mol Cell Endocrinol 2018, 477): 156-162.
52. Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, Parenti M, Chini B: Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 2003, 38(22): 6054-6060.
53. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA: Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005, 12(90): 6472-6479.
54. Corona G, Petrone L, Mannucci E, Jannini EA, Mansani R, Magini A, Giommi R, Forti G, Maggi M: Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004, 5(46): 615-622.

Tables

Table 2 Number of potentially active compounds per herb and the number of targets

| Herbal name | Potential active compound number | Targets Number |
|-------------|---------------------------------|----------------|
| MO          | 16                              | 55             |
| AR          | 4                               | 78             |
| HM          | 17                              | 206            |
| PR          | 8                               | 81             |
| RD          | 12                              | 76             |
| RB          | 13                              | 189            |
| FF          | 19                              | 220            |
Table 3 PE disease PPI network cluster analysis

| Cluster | Scores | Nodes | Edges | Node |
|---------|--------|-------|-------|------|
| 1       | 11.857 | 15    | 83    | PARP1, HIF1A, MYC, BRCA1, SMAD2, CREBBP, SP1, MAPK1, SMAD4, MAPK3, SMAD3, TP53, EP300, ESR2, CTNNB1 |
| 2       | 7.267  | 31    | 109   | FAS, GAPDH, PDGFRB, SMARCA4, PDGFRA, RUNX2, EGFR, JUN, JUP, CASP8, STAT5B, GADD45A, IGFlR, EZR, ESR1, STAT1, AKT1, NFKB1, XRCC6, FADD, TNFRSF1A, VDR, ERBB2, RHOA, NR3C1, MAPK14, ETS1, FOXO3, AR, PPARG, FASLG |
| 3       | 6.786  | 29    | 95    | ANXA2, KDM1A, SIRT1, MAP2K2, BRCA2, MAPK8, BRAF, BMX, JAK2, JAK1, STAT3, SRC, TERT, CXCR4, CDKN1A, GHR, PIK3R1, PIK3CA, RB1, RAF1, PTPRC, EZH2, FLNA, MUC1, CCR5, SOS2, SOS1, NTRK1, GRB2 |
Table 4 Clusters within the QSD-PE PPI network

| Cluster | Score  | Node | Edges | Node                          |
|---------|--------|------|-------|-------------------------------|
| 1       | 4.889  | 10   | 22    | CASP8, RB1, CASP7, RUNX2, NR3C1, MTOR, EGFR, AR, SIRT1, TP53 |
|         |        |      |       | JUN, NFE2L2, MDM2, MAPK8, MAPK14, PARP1, CDKN1A, PPARG, GSTP1, CDKN2A |
| 2       | 4.667  | 10   | 21    | MYC, MAPK1, TOP2A, HIF1A, RAF1, ESR1 |
| 3       | 4.400  | 6    | 11    |                              |

Additional File Legends

**Figure S1.** PPI network of module 1 derived from the PPI network of PE-related targets.

**Figure S2.** PPI network of module 2 derived from the PPI network of PE-related targets.

**Figure S3.** PPI network of module 3 derived from the PPI network of PE-related targets.

**Figure S4.** The pathway-targets network of the PE-related targets.

**Table S1.** The chemical parameters of the active compounds in QS formula.

**Table S2.** The detail information of the compounds-compounds targets network.

**Table S3.** The PE-related targets retrieved from databases.

**Table S4.** The detailed information of the disease PPI network.

**Table S5.** GO analysis results of the QS formula-PE targets.

**Table S6.** GO analysis results of the module 1 derived from the QS formula-PE targets.

**Table S7.** GO analysis results of the module 2 derived from the QS formula-PE targets.

**Table S8.** GO analysis results of the module 3 derived from the QS formula-PE targets.

**Table S9.** Detailed topological characteristics of gene-pathways network of PE-related targets.

**Table S10.** GO enrichment analysis results of QS formula-PE targets.
Table S11. KEGG enrichment analysis results of QS formula-PE targets.

Table S12. Details of topological characteristics of the QS formula-PE network.

Figures

Figure 1

Workflow for Qiaoshao formula in the treatment of premature ejaculation.
Figure 2

The Qiaoshao formula compound-compound target network (Purple quadrilaterals, green circles, and blue triangles represent herbs, compounds, and targets, respectively)
Figure 3

PPI network of PE-related targets.
Figure 4

PPI network of QS formula-PE targets and modules, (a) PPI network of QS formula-PE targets, (b-d) module analysis of PPI network of QS formula-PE targets. Yellows nodes represent key targets.
Figure 5
Pathways of the QS formula-PE targets network. Blue hexagons and green circles represent pathways and targets, respectively.
Figure 6

Herbs-compounds-targets-pathway network (Purple indicates herbs; green indicates compounds; pink indicates targets; orange indicates pathways).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS4.csv
- TableS8.xlsx
- TableS11.xlsx
- TableS12.csv
- TableS5.xlsx
- TableS10.xlsx
- TableS1.xlsx
- TableS9.csv
- TableS3.xlsx
- TableS7.xlsx
- TableS6.xlsx
- TableS2.csv
- FigureS4.pdf
- FigureS2.pdf
- FigureS3.pdf
- FigureS1.pdf